We recently contacted all stakeholders for the appraisal of tofacitinib for treating active ankylosing spondylitis regarding a delay to this topic for operational reasons.
Tofacitinib for treating active ankylosing spondylitis has now been rescheduled into the work programme. The appraisal is due to start late September 2021 and will be discussed at committee in early June 2022. This appraisal will now follow the Single Technology Appraisal Process and will not be included in a Multiple Technology Appraisal with Upadacitinib for treating active ankylosing spondylitis [ID3848] as originally advised.
The new timelines are subject to the work programme capacity and we will continue to review our plans in collaboration with the company and update our stakeholders accordingly.